PROLOR Biotech Inc

PROLOR Biotech — Leerink Swann Hot Topics Roundtable Conference 2011

18 slides from PROLOR Biotech's conference presentation, Feb 16, 2011

  1. Slide 1: Protein. Longevity. Redefined - Corporate Presentation

    BIOTECH Protein.Longevity. Redefined Corporate Presentation Leerink Swann Hot Topics Roundtable Conference February 16-17, 2011 NYSE Amex: PBTH

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement EEE This presentation contains forward-looking statements, including statements regarding the results of current studies and pre-clinical experiments and the effectiveness of PROLOR’s long-acting protein programs and are made pursuant to the safe harbor provisions of the Privat

  3. Slide 3: PROLOR: Leader in BioBetter Drugs

    PROLOR: Leader in BioBetter Drugs Developing CTP-enhanced biobetter proteins and peptides O Dramatically reduce injection frequency, drug load and potentially side-effects for most proteins, peptides or antibodies Validated platform technology — safe and effective 0 Based on natural human peptide pr

  4. Slide 4: CTP: Clinically Validated Technology

    CTP: Clinically Validated Technolog Merck ‘s long-acting FSH-CTP (Elonva®) received EU marketing authorization in 2010 O Single FSH-CTP injection replaces 7 daily FSH injections in fertility treatment Two licensees of CTP technology: PROLOR and Merck G Merck holds license for 4 fertility-focused pro

  5. Slide 5: Lead Product: hGH-CTP BioBetter to Reduce Injection Frequency

    Lead Product: hGH-CTP BioBetter to Reduce Injection Frequency * $3 billion market * Growing at 7% annually * Requires daily injections

  6. Slide 6: hGH-CTP Phase II Trial Ongoing

    hGH-CTP Phase II Trial Ongoing 48-56 GHD adults, 4 cohorts, repeated injections, escalating dose O 1x per week and 2x per month All currently on daily hGH treatment Stop daily injections; replace with single weekly/biweekly injections Measure IGF-1 dose response levels and collect information to sel

  7. Slide 7: Phase II Trial On-Track

    Phase II Trial On-Track Patient enrollment and dosing proceeding according to schedule oO Most patients in trial are enrolled og Majority of participants have already received hGH-CTP Independent Data Safety Monitoring Board reviewed safety data on 2/9/2011 and concluded the study was safe to procee

  8. Slide 8: hGH-CTP Competitive Landscape Update

    hGH-CTP Competitive Landscape Update ee Orphan drug designation obtained in U.S. O Granted for treatment of growth hormone deficiency-- covers GH deficiency in both adults and children Novo Nordisk update Go Announced Oct 32 2010 that PEG-hGH program was terminated due to expected administration pro

  9. Slide 9: Factor IX BioBetter to Reduce Hospitalization

    Factor IX BioBetter to Reduce Hospitalization * Hemophilia B — $700 million market * Growing at 14% annually * Bleeding events require hospitalization * Prophylactic treatment requires 2 weekly IV infusions administered in hospital

  10. Slide 10: Factor IX-CTP Efficacy

    Factor IX-CTP Efficacy Comparative Study in Factor IX-depleted mice 48 Hours 10 Min_15 Min 10 Min 12 Hours v Rest Factor IX injection Bleeding Event Spontaneous Bleeding RE-Bleeding Event Observation Stop Bleeding Event For animals still bleeding Designed to test Duration of clotting activity Qualit

  11. Slide 11: Clotting activity when compared to the Factor-IX-CTP treated group

    Clotting activity when compared to the Factor-IX-CTP treated group First bleeding event Lost 2.8x more blood Lost 2x more blood Long-acting clotting activity when compared to the Factor-IX-CTP treated group Second bleeding event Lost 4.6x more blood Lost 3.8x more blood Bleeding duration Bleeding ep

  12. Slide 12: Added 2nd drug delivery technology platform: Reversible PEGylation

    Added 2"! drug delivery technology platform for peptides & small molecules — Reversible PEGylation SSC“ SSC + PEG chain too large for small peptide, i. \ 3 ~ STANDARD PEGYLATION rendering it inactive, or must be used in very high doses + PEG chain hydrolyzed from small peptide, Hydrolysis i" leaving

  13. Slide 13: Obesity Epidemic Demands New Safe & Effective Therapies

    Obesity Epidemic Demands New Safe & Effective Therapies Recent FDA rejections focus on safety issues —Vivus — Risk of major adverse cardiovascular events; Risk of birth defects — Arena — Risk of heart-valve disease, psychiatric and memory problems and cancerous tumors in rats — Orexigen — Risk of ma

  14. Slide 14: Oxyntomodulin - Nature's Appetite Control Mechanism

    Oxyntomodulin— Nature’s Appetite Control Mechanism Satiety + Natural appetite suppressant mechanism i * Can be over-expressed in very high quantities with no side effects * Preclinically achieved 0.5kg per week — oe — weight loss over 4 weeks along with signs : barrier of adipose tissue loss* aor *

  15. Slide 15: 2011 Pipeline Development Focus

    2011 Pipeline Development Focus ee Oxyntomodulin Go Complete further animal efficacy and tox studies O File for regulatory clearance to initiate Phase | Factor IX, Factor Vil Oo Complete further animal efficacy and tox studies O File for regulatory clearance to initiate Phase II Atherosclerosis, Rhe

  16. Slide 16: Anticipated Milestones

    Anticipated Milestones Event Atherosclerosis, Rheumatoid Arthritis: Production Q4 2010 Obesity: Complete efficacy studies in small animals Ql 2011 Factor Complete efficacy studies in hemophilic small @12011 hGH-CTP: Phase II adult clinical trial completion Q2 2011 hGH-CTP: Phase III adult study regu

  17. Slide 17: Leadership

    Leadership Chairman prewray _—_ Abraham Havron, Ph.D. erono Ret SAVIENT CEO Jane Hsiao, Ph.D., MBA VAX. OPKO Director A Corporation Marian Gorecki, Ph.D. MediWound Director Steve Rubin, J.D. VAX. OPKO Director Corporation Shai Novik, MBA cr z me c: 2 os

  18. Slide 18: Financial Profile

    Financial Profile ee NYSE-Amex and TASE listed (PBTH) 54 million common shares outstanding, 60 million fully diluted, 27 million shares in the float $24 million cash balance September 30, 2010 Cash expected to last through 2012 PROLOR BI

PROLOR Biotech — Leerink Swann Hot Topics Roundtable Conference 2011 on 6ix